Safety and Tolerability of Ruxolitinib Cream in Adolescents with Mild-to-Moderate Atopic Dermatitis: Results From a 1-Year, Phase III, Open-Label Study
{{output}}
Background: Ruxolitinib cream (1.5%) has demonstrated efficacy and safety in patients aged ≥ 2 years with mild-to-moderate atopic dermatitis. Objective: ... ...
